PolyNovo Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
PolyNovo Stock Forecast and Price Target
The average target price set lately by experts for PolyNovo to reach by the end of the year is $2.14, which would imply a potential upside of approximately 2.39 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of $2.75 and a low estimate of $1.00. Even if you're not interested in PNV stock, you may be interested in its competitors.
2.39% Upside
PolyNovo Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, PolyNovo's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $2.12, which would mean an increase of 100.00%. Over the next eight years, experts predict that PolyNovo's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
12
|
$275.80 | Buy/Sell | $205.51 | -26.34% |
| TLX Stock Forecast | Telix Pharmaceuticals | Buy |
6
|
$15.24 | Buy/Sell | $13.37 | -4.86% |
| NEU Stock Forecast | Neuren Pharmaceuticals | Buy |
11
|
$19.70 | Buy/Sell | $26.43 | 34.92% |
| CUV Stock Forecast | Clinuvel Pharmaceuticals | Buy |
16
|
$14.86 | Buy/Sell | $27.41 | 49.73% |
| IMU Stock Forecast | Imugene | Buy |
4
|
$0.08 | Buy/Sell | $0.35 | 425.00% |
PolyNovo Revenue Forecast for 2023 - 2025 - 2030
In the last three years, PolyNovo's Revenue has grown by 195.94%, rising from $22.19M to $65.67M. For next year, analysts predict Revenue of $94.69M, which would mean an increase of 44.19%. Over the next nine years, experts predict that PolyNovo's Revenue will grow at a rate of 158.47%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IMM Stock Forecast | Immutep | Buy |
8
|
$0.44 | Buy/Sell | $1.26 | 127.27% |
| MSB Stock Forecast | Mesoblast | Buy |
9
|
$1.09 | Buy/Sell | $0.69 | 0.92% |
| PYC Stock Forecast | PYC Therapeutics | Buy |
8
|
$0.11 | Buy/Sell | $0.30 | 227.27% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CGS Stock Forecast | Cogstate | Buy |
11
|
$1.40 | Buy/Sell | $1.85 | 28.57% |
| BOT Stock Forecast | Botanix Pharmaceuticals | - |
0
|
$0.19 | Buy/Sell | $0.00 | -100.00% |
| DXB Stock Forecast | Dimerix |
0
|
$0.36 | Buy/Sell | $0.00 | 61.11% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACW Stock Forecast | Actinogen Medical |
5
|
$0.03 | Buy/Sell | $0.15 | -100.00% | |
| BIT Stock Forecast | Biotron | - |
0
|
$0.05 | Buy/Sell | $0.00 | -100.00% |
| SPL Stock Forecast | Starpharma Holdings | - |
8
|
$0.12 | Buy/Sell | $0.95 | -100.00% |
PolyNovo EBITDA Forecast for 2023 - 2025 - 2030
PolyNovo's EBITDA has seen impressive growth In the last three years, rising from $-3.55M to $-3.75M – a growth of 5.63%. For the next year, 6 analysts project PolyNovo's EBITDA to drop by 170.13%, reaching $2.63M. By 2030, professionals believe that PolyNovo's EBITDA will decrease by 4657.33%, reaching $170.90M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IVX Stock Forecast | Invion | - |
0
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
| PTX Stock Forecast | Prescient Therapeutics |
2
|
$0.05 | Buy/Sell | $0.20 | 180.00% | |
| CYP Stock Forecast | Cynata Therapeutics |
0
|
$0.24 | Buy/Sell | $1.24 | 416.67% |
PolyNovo EBIT Forecast for 2023 - 2025 - 2030
In the last three years, PolyNovo's EBIT has grown by 25.68%, rising from $-4.05M to $-5.09M. According to 3 prominent analysts, PolyNovo's EBIT will fall by 120.43% in the next year, reaching $1.04M. By 2030, professionals believe that PolyNovo's EBIT will decrease by 1435.95%, reaching $68.00M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1AI Stock Forecast | Algorae Pharmaceuticals | - |
-4
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
| IMC Stock Forecast | Immuron | - |
0
|
$0.07 | Buy/Sell | $0.00 | -100.00% |
| ATH Stock Forecast | Alterity Therapeutics | - |
0
|
$0.00 | Buy/Sell | $0.75 | 0.00% |
PolyNovo EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, PolyNovo's EPS has grown by 100.00%, rising from $-0.01 to $0.00. For next year, analysts predict EPS of $0.00, which would mean an increase of 100.00%. Over the next eight years, experts predict that PolyNovo's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GTG Stock Forecast | Genetic Technologies | - |
0
|
$0.12 | Buy/Sell | $1.00 | -100.00% |
| OSL Stock Forecast | OncoSil Medical | - |
0
|
$0.01 | Buy/Sell | $0.11 | -100.00% |
| ATX Stock Forecast | Amplia Therapeutics | - |
0
|
$0.06 | Buy/Sell | $7.30 | -100.00% |
.jpg)